Alexander Ahn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexander Ahn has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Kenia de Los Santos-Alexis
Department of Microbiology and Immunology, Columbia University, New York, NY 10032, USA
2 shared publications - Nicholas Arpaia
Department of Microbiology and Immunology, Columbia University, New York, NY 10032, USA
2 shared publications - Rosa L. Vincent
Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA
2 shared publications - Tal Danino
Department of Biomedical Engineering, Columbia University, New York, NY, USA
2 shared publications - Thomas M. Savage
Department of Microbiology & Immunology, Columbia University, New York, NY 10032, USA
2 shared publications - Courtney Coker
Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA
1 shared publication
Latest Publications
- 18 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (100) , eadn9879
Programmable bacteria synergize with PD-1 blockade to overcome cancer cell–intrinsic immune resistance mechanisms
Interferon-γ (IFN-γ) is a potent cytokine critical for response to immunotherapy, yet conventional methods to systemically deliver this cytokine have been hindered by severe dose-limiting toxicities. Here, we engineered a strain of probiotic bacteria that home to tumors and locally release IFN-γ. A single intratumoral injection of these IFN-γ–producing bacteria was sufficient to drive systemic tumor antigen–specific antitumor immunity, without observable toxicity. Although cancer cells use various resistance mechanisms to evade immune responses, bacteria-derived IFN-γ overcame primary resistance to programmed cell death 1 (PD-1) blockade via activation of cytotoxic Foxp3 − CD4 + and CD8 + T cells. Moreover, by activating natural killer (NK) cells, bacteria-derived IFN-γ also overcame acquired resistance mechanisms to PD-1 blockade, specifically loss-of-function mutations in IFN-γ signaling and antigen presentation pathways. Collectively, these results demonstrate the promise of combining IFN-γ–producing bacteria with PD-1 blockade as a therapeutic strategy for overcoming immunotherapy-resistant, locally advanced, and metastatic disease.
- 18 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (100) , eadn9879
Programmable bacteria synergize with PD-1 blockade to overcome cancer cell–intrinsic immune resistance mechanisms
Interferon-γ (IFN-γ) is a potent cytokine critical for response to immunotherapy, yet conventional methods to systemically deliver this cytokine have been hindered by severe dose-limiting toxicities. Here, we engineered a strain of probiotic bacteria that home to tumors and locally release IFN-γ. A single intratumoral injection of these IFN-γ–producing bacteria was sufficient to drive systemic tumor antigen–specific antitumor immunity, without observable toxicity. Although cancer cells use various resistance mechanisms to evade immune responses, bacteria-derived IFN-γ overcame primary resistance to programmed cell death 1 (PD-1) blockade via activation of cytotoxic Foxp3 − CD4 + and CD8 + T cells. Moreover, by activating natural killer (NK) cells, bacteria-derived IFN-γ also overcame acquired resistance mechanisms to PD-1 blockade, specifically loss-of-function mutations in IFN-γ signaling and antigen presentation pathways. Collectively, these results demonstrate the promise of combining IFN-γ–producing bacteria with PD-1 blockade as a therapeutic strategy for overcoming immunotherapy-resistant, locally advanced, and metastatic disease.
- Top Cited Papers
- 10 March 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (10) , eadc9436
Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity
Tumors use multiple mechanisms to actively exclude immune cells involved in antitumor immunity. Strategies to overcome these exclusion signals remain limited due to an inability to target therapeutics specifically to the tumor. Synthetic biology enables engineering of cells and microbes for tumor-localized delivery of therapeutic candidates previously unavailable using conventional systemic administration techniques. Here, we engineer bacteria to intratumorally release chemokines to attract adaptive immune cells into the tumor environment. Bacteria expressing an activating mutant of the human chemokine CXCL16 (hCXCL16 K42A ) offer therapeutic benefit in multiple mouse tumor models, an effect mediated via recruitment of CD8 + T cells. Furthermore, we target the presentation of tumor-derived antigens by dendritic cells, using a second engineered bacterial strain expressing CCL20. This led to type 1 conventional dendritic cell recruitment and synergized with hCXCL16 K42A -induced T cell recruitment to provide additional therapeutic benefit. In summary, we engineer bacteria to recruit and activate innate and adaptive antitumor immune responses, offering a new cancer immunotherapy strategy.
- 10 March 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (10) , eadc9436
Top Cited PapersChemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity
Tumors use multiple mechanisms to actively exclude immune cells involved in antitumor immunity. Strategies to overcome these exclusion signals remain limited due to an inability to target therapeutics specifically to the tumor. Synthetic biology enables engineering of cells and microbes for tumor-localized delivery of therapeutic candidates previously unavailable using conventional systemic administration techniques. Here, we engineer bacteria to intratumorally release chemokines to attract adaptive immune cells into the tumor environment. Bacteria expressing an activating mutant of the human chemokine CXCL16 (hCXCL16 K42A ) offer therapeutic benefit in multiple mouse tumor models, an effect mediated via recruitment of CD8 + T cells. Furthermore, we target the presentation of tumor-derived antigens by dendritic cells, using a second engineered bacterial strain expressing CCL20. This led to type 1 conventional dendritic cell recruitment and synergized with hCXCL16 K42A -induced T cell recruitment to provide additional therapeutic benefit. In summary, we engineer bacteria to recruit and activate innate and adaptive antitumor immune responses, offering a new cancer immunotherapy strategy.